Related Experiment Video
Updated: Mar 11, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor
Jessica Charlet1, Ayumi Tomari1, Anthony R Dallosso1
1School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Abstract:
Neuroblastoma is a childhood cancer in which many children still have poor outcomes, emphasising the need to better understand its pathogenesis. Despite recent genome-wide mutation analyses, many primary neuroblastomas do not contain recognizable driver mutations, implicating alternate molecular pathologies such as epigenetic alterations. To discover genes that become epigenetically deregulated during neuroblastoma tumorigenesis, we took the novel approach of comparing neuroblastomas to neural crest precursor cells, using genome-wide DNA methylation analysis. We identified 93 genes that were significantly differentially methylated of which 26 (28%) were hypermethylated and 67 (72%) were hypomethylated. Concentrating on hypermethylated genes to identify candidate tumor suppressor loci, we found the cell engulfment and adhesion factor gene MEGF10 to be epigenetically repressed by DNA hypermethylation or by H3K27/K9 methylation in neuroblastoma cell lines. MEGF10 showed significantly down-regulated expression in neuroblastoma tumor samples; furthermore patients with the lowest-expressing tumors had reduced relapse-free survival. Our functional studies showed that knock-down of MEGF10 expression in neuroblastoma cell lines promoted cell growth, consistent with MEGF10 acting as a clinically relevant, epigenetically deregulated neuroblastoma tumor suppressor gene. © 2016 The Authors. Molecular Carcinogenesis Published by Wiley Periodicals, Inc.
Insights
Neuroblastoma, a childhood cancer, often lacks driver mutations, suggesting epigenetic causes. Researchers identified MEGF10 as a tumor suppressor gene repressed by hypermethylation, impacting patient survival.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Neuroblastoma is a prevalent childhood cancer with poor outcomes.
- Many neuroblastomas lack identifiable driver mutations, indicating alternative pathologies like epigenetic alterations.
- Understanding neuroblastoma pathogenesis requires investigating epigenetic deregulation.
Purpose of the Study:
- To identify epigenetically deregulated genes in neuroblastoma tumorigenesis.
- To compare DNA methylation patterns between neuroblastomas and neural crest precursor cells.
- To investigate the role of the MEGF10 gene in neuroblastoma development.
Main Methods:
- Genome-wide DNA methylation analysis comparing neuroblastoma and neural crest precursor cells.
- Identification and characterization of differentially methylated genes.
- Functional studies involving MEGF10 gene expression knockdown in neuroblastoma cell lines.
Main Results:
- Identified 93 differentially methylated genes, with 26 hypermethylated and 67 hypomethylated.
- Found MEGF10 epigenetically repressed by DNA hypermethylation or H3K27/K9 methylation.
- MEGF10 expression was significantly down-regulated in neuroblastoma tumors, correlating with reduced relapse-free survival.
- Knockdown of MEGF10 promoted neuroblastoma cell growth.
Conclusions:
- MEGF10 acts as a tumor suppressor gene in neuroblastoma.
- Epigenetic repression of MEGF10 contributes to neuroblastoma pathogenesis.
- MEGF10 deregulation is a clinically relevant finding for neuroblastoma patients.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Master Transcription Regulators
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

